Compare Digital Realty Trust, Inc. (DLR) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Digital Realty Trust, Inc. vs Illumina, Inc. — how do they compare? Digital Realty Trust, Inc. trades at $178.53 (market cap $65.32B), while Illumina, Inc. trades at $278.1 (market cap $39.95B). The key difference: Digital Realty Trust, Inc. is the larger of the two by market cap, and Digital Realty Trust, Inc. pays a 2.77% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Digital Realty Trust, Inc. for 93 Days and Illumina, Inc. for 83 Days on average.
| DLR | ILMN | |
|---|---|---|
Market Cap | $65.32B | $39.95B |
Volume | 2,563,950 | 3,169,503 |
Sector | Real Estate | Health |
52-Week High | $203.91 | $293.69 |
52-Week Low | $147.93 | $91.00 |
Typical Hold Time | 93 Days | 83 Days |
Enterprise Value | $84.03B | $41.31B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Digital Realty Trust (DLR) trades at $178.15, down 1.29% with a bearish technical outlook. The stock shows strong fundamentals with Q2 2026 EPS beating expectations at $1.21 versus $0.48 expected, and revenue growth from $6.11B in 2025 to projected $6.8B in 2026. Analyst consensus is strongly bullish with 34 buys and a $222.35 price target, supported by AI-driven data center demand and recent infrastructure expansions.
DLR presents a compelling growth opportunity driven by AI infrastructure demand, with record interconnection activity and strategic partnerships. Key risks include high valuation multiples (P/E 85.89) and significant capital expenditures. The technical bearish signal contrasts with strong fundamental momentum, creating potential for volatility near-term.
Illumina (ILMN) trades at $271.02, up 1.22% and near its 52-week high, reflecting strong momentum. The stock exhibits a bullish technical trend with recent earnings beats and a positive analyst consensus. Revenue for 2025 was $4.34B with net income of $850M, marking a significant profit margin recovery. Cash flow from operations remains robust at $1.08B, supporting financial stability. Inclusion in the S&P 500 and focus on AI-driven genomics growth are key catalysts.
Outlook is positive given earnings momentum and strategic initiatives, but risks include valuation premiums and competitive pressures. The stock offers growth exposure to genomic innovation, though investors should monitor execution on AI integration and margin sustainability. Analyst price targets suggest moderate upside from current levels, with consensus at $241.00.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Digital Realty Trust, Inc.
Digital Realty owns and operates nearly 300 data centers worldwide. It has more than 35 million rentable square feet across five continents. Digital's offerings range from retail co-location, where an enterprise may rent a single cabinet and rely on Digital to provide all the accommodations, to cold shells, where hyperscale cloud service providers can simply rent much, or all, of a barren, power-connected building. In recent years, Digital Realty has de-emphasized cold shells and now primarily provides higher-level service to tenants, which outsource their related IT needs to Digital. Digital Realty has also moved more into the co-location business, increasingly serving enterprises and facilitating network connections. Digital Realty operates as a real estate investment trust.
Read more on DLR →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
